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Abstract
The ability to track microbes in real time in vivo is of enormous value for preclinical investigations in infectious disease or
gene therapy research. Bacteria present an attractive class of vector for cancer therapy, possessing a natural ability to grow
preferentially within tumours following systemic administration. Bioluminescent Imaging (BLI) represents a powerful tool for
use with bacteria engineered to express reporter genes such as lux. BLI is traditionally used as a 2D modality resulting in
images that are limited in their ability to anatomically locate cell populations. Use of 3D diffuse optical tomography can
localize the signals but still need to be combined with an anatomical imaging modality like micro-Computed Tomography
(mCT) for interpretation. In this study, the non-pathogenic commensal bacteria E.coli K-12 MG1655 and Bifidobacterium breve
UCC2003, or Salmonella Typhimurium SL7207 each expressing the luxABCDE operon were intravenously (IV) administered to
mice bearing subcutaneous (s.c) FLuc-expressing xenograft tumours. Bacterial lux signal was detected specifically in
tumours of mice post IV-administration and bioluminescence correlated with the numbers of bacteria recovered from
tissue. Through whole body imaging for both lux and FLuc, bacteria and tumour cells were co-localised. 3D BLI and mCT
image analysis revealed a pattern of multiple clusters of bacteria within tumours. Investigation of spatial resolution of 3D
optical imaging was supported by ex vivo histological analyses. In vivo imaging of orally-administered commensal bacteria
in the gastrointestinal tract (GIT) was also achieved using 3D BLI. This study demonstrates for the first time the potential to
simultaneously image multiple BLI reporter genes three dimensionally in vivo using approaches that provide unique
information on spatial locations.
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Introduction
The study of bacteria in small animal models is of high
importance to a range of medical research fields, including
infectious diseases, gut health and gene therapy. The value of
non-invasive, longitudinal monitoring of bacterial strains in vivo is
well accepted, not only because such methodologies drastically
reduce animal usage, but also the data generated are more
statistically relevant than end-point assays. The bacterial cells,
kinetics of transgene expression and host cell responses may be
quantitatively assessed simultaneously over time. BLI is based on
the detection of bioluminescent light from the subject through use
of a cooled charged coupled device (CCD) camera. The relatively
simple instrumentation and lack of requirement for radioactivity
puts the technology well within the reach of the average
laboratory.
Visualisation of bacteria in animal models has become
widespread in recent years [1,2]. The luxCDABE operon isolated
from Vibrio harveyi [3] and Photorhabdus luminescens (formerly
Xenorhabdus luminescens), amongst others, has enabled microbiolo-
gists to generate constitutively bioluminescent cells in a diverse
range of bacterial genera, without the necessity of exogenous
substrate [4]. The first experiments demonstrating in vivo detection
of a bioluminescent signal were reported in 1995 by Contag and
co-workers and involved the imaging of mice infected with lux-
tagged Salmonella Typhimurium [5]. Other luminescent gene
systems are also available for bacteria, such as beetle luciferases
which have been expressed in Bifidobacterium longum [6] and E. coli
[7]. Strains have also been engineered to express fluorescent
markers [8]. However, high background levels and poor tissue
penetration of both excitation and emission light restricts the
application of fluorescence in vivo to predominantly subcutaneous,
shallow depth models. Luminescence-based reporter systems
display fewer drawbacks, since autoluminescence is almost
nonexistent, allowing significantly higher sensitivity and specificity
than fluorescent reporters in vivo.
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In the context of gene therapy, the use of biological agents for
delivery of therapeutic genes to patients has shown great promise.
Like viruses, the innate biological properties of bacteria permit
efficient DNA delivery to cells or tissues, particularly in the context
of cancer. It has been shown that bacteria are naturally capable of
homing to tumours when systemically administered resulting in
high levels of replication locally, either external to (non-invasive
species) or within tumour cells (pathogens). This was originally
established following IV administration of species of Clostridium,
and in more recent years with numerous bacterial species,
including Salmonella, Bifidobacterium, Escherichia coli, Vibrio cholerae
and Listeria monocytogenes [9,10,11,12]. Strains of clostridia [13] and
salmonella have been investigated in clinical trials involving
tumour targeting [14,15,16]. Various factors are believed to be
involved in the tumour-specific nature of bacterial growth in vivo,
including low oxygen potential (hypoxia), irregular blood supply,
local immune suppression and unique nutrient availability within
necrotic tumour regions [17,18]. However, the precise mecha-
nisms involved in bacterial tumour targeting are poorly under-
stood and require rigorous research. Live imaging of mice has
shown systemically administered lux-tagged bacteria replicating
locally in tumours [1,19,20]. Yu et al. first reported in vivo BLI of
bacteria in tumours growing in mice following intravenous (IV)
administration of lux-labelled attenuated S. Typhimurium and
Vibrio cholerae [1].
BLI displays many benefits when compared with other in vivo
modalities. It is easy to use, inexpensive, rapid and facilitates
imaging of multiple animals simultaneously, producing little
background with high sensitivity. Traditionally, optical images
are two-dimensional and thus devoid of depth information. A
major limitation relates to poor spatial resolution, light scattering
and absorption by the tissue can substantially impact the 2D
measurement [21]. A recent comparative study of imaging
technologies reported that the BLI signal measured in vivo on
shaved mice was reduced 3-fold compared with the signal from the
same tumour ex vivo after excision [22]. Therefore, in our case, a
lux signal from deep tissue or within a tumour is dispersed and
does not pinpoint the precise source of the signal in a 2D image.
We propose to address these failings through use of 3D optical
tomography, in combination with mCT. For these investigations,
we employ non-pathogenic commensal bacteria that colonise both
the GIT and s.c tumours to high levels. We have engineered a
number of strains of Bifidobacterium and E. coli to express the
luxABCDE cassette. E. coli is part of the flora of the human GIT.
Several studies have outlined the safety of IV administration of
non-pathogenic E. coli strains to mice, and their ability to grow
specifically within tumours [18,23]. E. coli MG1655 (as used in this
study) colonises the mouse GIT to high levels [7]. Bifidobacteria
are a native, harmless resident of the human gut, and certain
bifidobacterial strains have been shown to have health-promoting
or probiotic benefits [24]. We have previously shown that B. breve
UCC2003 colonises mouse GIT [25] and various tumour models
in mice, not only post IV administration, but also following oral
GIT colonisation of mice [19]. This study examines the intra-
tissue growth of these lux-labelled bacteria in live mice both two
and three-dimensionally using in vivo BLI and mCT co-registration.
Results
1. Tumour-Related Growth of Pathogenic and Non-
Pathogenic Bacteria Following IV Administration
Bacterial homing to and replication within various subcutane-
ous tumours following IV administration was imaged over time
using 2D whole body BLI of mice. We compared the tumour-
specific replication ability of the non-pathogenic commensal
bacteria E. coli MG1655 and B. breve UCC2003 with that of the
most investigated species in the field, Salmonella Typhimurium
[26,27]. 16106 lux-expressing E.coli MG1655 or S. typhimurium
SL7207 or 16105 B. breve UCC2003 (corresponding to the
maximum tail-vein injectable dose, in terms of viscosity of
bacterial solution) were administered via tail vein injection to
athymic mice bearing subcutaneous Lewis Lung Carcinoma (LLC)
tumours (n = 6). 2D in vivo BLI was performed at various times post
bacterial administration. Lux signal was detected specifically in
tumours of mice 3–14 days post IV-administration of B. breve or E.
coli (Figure 1a,b). Unlike the non-pathogenic bacteria examined, S.
Typhimurium-related bioluminescence was also observed in areas
other than tumours, in particular, from the abdomen (at day 3)
and neck (at day 11) of the infected animals (Figure 1c). This
observation correlates well with previous studies, where growth
within the liver and spleen [5] was reported.
Subsequent BLI studies proceeded with the non-pathogenic
commensal bacteria. Bacterial replication in tumours was
confirmed by ex vivo bacterial culture and viable bacterial numbers
correlated with bioluminescence for each strain (Figure 2). Each
strain displayed characteristic levels of bioluminescence in tumours
(B. breve=0.12860.014; E. coli=0.37360.025 flux units per cfu,
on days 7–11). The relationship between bioluminescence and
bacterial counts followed linear trends (R2 values shown in
Figure 2). Because the activity of lux bioluminescence is dependent
on both FMNH2 and oxygen availability, lower bioluminescence/
cfu may be the result of decreased metabolic activity and/or
reduced oxygen availability at higher bacterial concentrations
and/or larger more hypoxic tumours.
To examine the range of tumour types applicable to bacterial
targeting, MG1655 or UCC2003 were IV administered to mice
bearing s.c. murine B16 melanoma, human U87 glioblastoma or
human FaDu hypopharyngeal carcinoma xenograft tumours.
Tumours were colonised in all cases, indicating that tumour
colonisation is independent of tumour type (Figure 1d).
2 Two- and Three-dimensional Bioluminescent Imaging
of Non-pathogenic Bacteria Following Oral
Administration
We have previously shown that oral administration of B. breve
UCC2003 leads to s.c. tumour colonisation at levels similar to IV
administration [19]. We routinely utilised bacterial culture to
demonstrate high-level GIT colonisation following oral gavage
with this strain [25]. Here, we examined the ability to in vivo image
bacteria within the GIT. The 2D image in Figure 3a indicates the
presence of B. breve UCC2003 in the abdominal region 9 days post
oral administration. Similarly, E. coli MG1655 was readily 2D
imaged in the region of the GIT post oral administration
(Figure 3b), with a more defined/localised pattern of light due to
the higher bioluminescence emitted by this strain. Diffuse optical
tomography (Figure 3d, Movie S1) in combination with a GIT
segmented from the mouse anatomical atlas revealed E. coli
luminescence localised in the general area of the GIT. Peak
luminescence levels were observed within the large intestine
region, correlating with results obtained by sampling and culturing
bacteria from different regions of the GIT (Figure 3c). A movie
depicting rotational 3D tomography can be seen in (Movie S1).
3 Co-localisation of Bacterial lux and Tumour-related
FLuc Bioluminescence
For cancer gene therapy, the ability to establish vector targeting
of malignant versus healthy tissue is of immense value. Through
Bacterial Bioluminescent Imaging
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sequential whole body imaging for tumour-associated FLuc and
bacterial lux signals, we demonstrate the potential for co-localising
these bioluminescent signals. Figure 4a shows a representative 2D
image overlay of tumour and bacterial bioluminescence, demon-
strating the location of each specifically in the tumour region. 2D
imaging lacks depth information, and therefore the pattern of
surface bioluminescence in the image output appears to be
dispersed throughout the tumour. Figure 4b shows sample 3D
images, providing tomographic detail of source signal distribution.
3D information indicates non-uniform distribution of both
Figure 1. Bacterial Growth in Tumours. (a,b) Bioluminescence from B. breve UCC2003, E. coli MG1655 or S. Typhimurium SL7207 in s.c. LLC
tumour bearing mice 11 days following IV delivery. Representative mice are shown. Increase in bacterial bioluminescence in tumours was observed
over time (n = 6). Data graphed represent the mean 6 S.E. There was no detectable bioluminescence in organs of treated animals, except for S.
Typhimurium (c) Representative S. Typhimurium administered mice displaying non-tumour-specific bacterial bioluminescence. Ventral image – Day 3,
Dorsal – Day 11. (d) All tumour types examined were colonised by the various strains. (i) B. breve, B16, Day 11 (ii) E. coli, FaDu, Day 7 (iii) B. breve, U87,
Day 14.
doi:10.1371/journal.pone.0030940.g001
Bacterial Bioluminescent Imaging
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bacterial and tumour signals. B. breve lux was observed in
multiple disparate ‘clusters’ within the tumour (Movie S2). Ex vivo
imaging of tissue sections of cherry fluorescent protein-expressing
B. breve/pCheMC and GFP-expressing tumours (U87-fLuc2/
GFP) (Figure 5), confirmed the non-uniform distribution of B.
breve, primarily in less viable regions of tumour, as evidenced by
low levels of GFP signal surrounding the bacterial cherry signal,
in tissue sections taken from the centre of tumours (Figure 5). By
contrast, no cherry signal was visible in tissue sections taken at
the periphery of tumours, which were highly populated with
GFP-positive cells (data not shown). Immunohistochemical
staining for endothelial cells (CD31) further highlighted the
concentration of vasculature in regions of higher viable tumour
cell density (Figure S1).
Figure 2. Relationship Between Bacterial Numbers And Bioluminescence. Viable bacteria in tumours were enumerated by ex vivo bacterial
culture from LLC tumours subsequent to BLI at various time-points post IV administration of B. breve or E. coli (n = 6). (a) Bacterial replication in
tumours. Increases over time in viable bacterial numbers and bioluminescence. Data graphed represent the mean6 S.E. (b) Correlation between
bacterial numbers and bioluminescence in tumours. Direct comparison between photon flux and bacterial colony counts. Log values of
bacterial numbers relative to in vivo bioluminescent units are graphed. Correlation between bacterial counts and bacterial bioluminescence signals:
R2 = 0.84 for B. breve: R2 = 0.97 for E. coli which correlates well with previous studies using E. coli MG1655 where R2 = 0.94, P,0.001 [57].
doi:10.1371/journal.pone.0030940.g002
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4 Co-registration of BLI and mCT
Mice bearing s.c. HCT116-luc2 tumours (average volume
120 mm3) 10 days post administration with B. breve UCC2003
were 3D BLI imaged, followed immediately by mCT imaging. Co-
registration of 3D BLI and mCT facilitated the anatomical
positioning of bioluminescent signal sources within the tumour
(Figure 6), in addition to visualisation of tumour vasculature
through administration of a contrast agent. Software image
analysis focussed on the tumour permitted partial assessment of
the intra-tumoural location of bacteria (Figure 6b, Movie S3). A
portion of the bacterial signal appeared to be co-localized within
the tumour with a rendering of the main tumour vasculature
around the tumour base.
Discussion
While determination of bacterial distribution and cell numbers
present over time can be achieved to some extent through the use
of traditional ex vivo analytical methods (culture, histology etc.),
these end-point assays are labour-intensive and expensive,
requiring the death of large numbers of animals, with high-
throughput experimentation difficult to achieve [28]. We demon-
strate here, the usefulness of BLI in permitting in vivo detection of
viable bacteria, empowering the investigator with the ability to
non-invasively assess bacterial trafficking and growth over time
with precision. We assessed the trafficking of two non-pathogenic
strains (a Gram-positive and a Gram-negative genus) in tumour-
Figure 3. Bacterial Bioluminescence in the GIT. The GIT of mice was colonised with either B. breve or E. coli by oral administration of 109 cfu of
the relevant strain for three consecutive days. (a) 2D image of athymic mouse 9 days post final feed with B. breve UCC2003/lux. (b) IVIS XR 2D
bioluminescence overlayed with X-ray image of mouse 27 days-post feeding with E. coli MG1655/lux. (c) Bacterial counts in specific regions of the GIT
14 days post feeding. Abdominal bioluminescence corresponding to average cfu is also shown (black dots). Data graphed represent the mean 6 S.E.
(d) Sample isolated images from 3D tomography of mouse from (b). 3D images show a digital mouse atlas of the skeleton to provide anatomical
registration. (Movie available in Movie S1). E. coli MG1655 bioluminescence is visible in blue at lower, and white or green at higher levels.
doi:10.1371/journal.pone.0030940.g003
Bacterial Bioluminescent Imaging
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Figure 4. Co-localisation of Tumour And Bacterial Bioluminescence. (a) 2D bioluminescence co-registration. Athymic mouse bearing
s.c. FLuc expressing FaDu tumour 7 days post IV administration of B. breve. Tumour FLuc =Green, Bacterial lux = orange. (b) 3D bioluminescence
co-registration. 3D overlay of B. breve lux (orange) 10 days post administration to athymic mice bearing HCT116 FLuc (green) expressing tumours.
doi:10.1371/journal.pone.0030940.g004
Figure 5. Ex vivo histological analysis. Fluorescent bacterial and tumour cells were imaged using fluorescence microscopy (Nuance). Blue- DAPI
(nuclei), Green- U87/GFP, Magenta- B. breve/pCheMC.
doi:10.1371/journal.pone.0030940.g005
Bacterial Bioluminescent Imaging
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bearing mice, and compared these data with those obtained using
the ‘gold-standard’ cancer therapy strain S. Typhimurium.
Various preclinical therapeutic trials have shown the ability of
different bacterial strains to traffic to tumour sites, primarily in the
context of delivery of DNA for subsequent tumour cell expression.
Pathogenic invasive species are utilised for this purpose [29]. S.
Typhimurium has been examined in clinical trials for tumour
targeting [14,15,16]. However, even with safety attenuation, the
inherent pathogenicity and immunogenicity of these bacteria has
outweighed therapeutic responses in patients. To address these
failings, we explored the use of non-pathogenic bacteria and
validated that these strains colonise tumours with efficiencies
similar to the best-described species in the field, S. Typhimurium.
The E. coli and B. breve strains employed here are non-invasive. In
the context of gene and cell therapy, such bacteria do not act as
cell transfection agents, but rather replicate within the tumour
stroma, external to tumour cells. Therapeutic strategies employing
these bacteria are analogous to cell therapy approaches, with
bacterial expression of therapeutic genes (e.g. anti-angiogenic or
immune modulating) within the environment of the tumour [10].
The non-invasive nature of these strains bestows further tumour-
specificity and safety, as was indicated here with B. breve and E. coli,
where their bioluminescence was confined to just tumours, unlike
that of S. Typhimurium which was also observed elsewhere in the
animal.
The E. coli and S. Typhimurium strains in this study were
labelled by genomic integration of the lux operon. p16sLux
integrates in single copy into the 16s rDNA site in the chromosome
of Gram-negative strains [30]. The use of a site-specific integrating
plasmid permits labelling of bacteria without interference in the
behaviour of the strain following integration. Bifidobacteria are
much less genetically tractable, and such genomic integration
strategies are unavailable. The lower levels of bioluminescence
observed from B. breve are likely to reflect lower lux gene
expression compared with E. coli and Salmonella, given the nature
of the episomal plasmid construct, but might also be reflective of
lower metabolic activity within this particular bacterium (this is
currently being investigated). Nonetheless, the pMC3 plasmid-
based lux system used here proved sufficiently robust to permit BLI
tracking in a range of situations, and this system is still the only
reported luxABCDE expression system for bifidobacteria [25].
Fluorescent protein tagging also proved useful in this study for ex
vivo analysis of B. breve in tumour tissue, since to date we have been
unable to visualise this strain in tumours by Gram-staining. Use of
the cherry red fluorescent strain, in conjunction with a green
fluorescent tumour cell line validated and provided further detail
on in vivo findings with 3D BLI.
While other studies using 2D BLI have demonstrated localisation
of bacteria to various regions of the mouse body (abdomen, lung, s.c.
tumour etc.), no depth information is available with 2D imaging.
The 2D image obtained is at the level of the animal surface and is
dispersed over an area broader than the source. This poor spatial
resolution limits conclusions that can be drawn. This is exemplified
in Figure 4a, where 2D imaging suggests that bacteria are
distributed throughout the tumour, whereas 3D tomography
(Movie S2) elucidates brighter source locations and implies that
the bacteria are concentrated non-uniformly within the tumour
mass. The histological analysis confirmed the presence of B. breve in
clusters, primarily in less viable regions of tumour as evidenced by
less green cells. While DAPI-stained nuclei were present proximal to
bacteria, the absence of GFP suggests that DAPI-positive cells are
not metabolically active U87 cells, and may relate to other cell types
of tumour stroma, such as immune or fibroblast. It should be noted
that tissue sections were 6 mm in thickness, and therefore not all cells
visualised are in the same plane.
Bifidobacterial growth in non-viable tumour regions has
previously been established by us and others. As tumours grow
over 2 mm3, the vascular supply becomes inadequate to supply
metabolic demands, resulting in areas of hypoxia. There are
multiple areas in tumours with ,1% oxygen compared with a
standard 3–15% in normal tissues. This is apparent with 3D
imaging in Figure 4b, where FLuc bioluminescence from U87
tumours is seen to be non-uniform throughout the tumour. Early
observations with strictly anaerobic bacteria (clostridia and
bifidobacteria) lead to the hypothesis that, unlike normal tissues,
hypoxic environments in tumours provide anaerobic growth
Figure 6. Co-registration with mCT. (a) Whole Body 3D co-registration of lux, FLuc and mCT. Combined luminescence and mCT
demonstrating co-localisation of B. breve (bacterial lux - orange) and subcutaneous HCT116-luc2 tumour (FLuc - green). (b) Intratumoural Imaging.
Combined mCT and luminescence imaging. Magnification of subcutaneous tumour from mouse in (a), top, side and base view. Viable tumour (FLuc
green/blue), vasculature (contrast agent – red) and bacterial (orange/yellow) signals are visualised. Movie on website (Movie S3).
doi:10.1371/journal.pone.0030940.g006
Bacterial Bioluminescent Imaging
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conditions resulting in tumour-specific bacterial growth [31,32].
However, the precise mechanism of tumour-specific bacterial
growth has yet to be demonstrated. Entry, survival and replication
of bacteria in tumours may also involve the leaky vasculature of
tumours and the tumour immune microenvironment which
provides a sanctuary for bacteria to escape the immune system
[1]. The nutrient rich environment created by cell death in
necrotic regions may also play an important role as evidenced by
findings that tumours can support the replication of auxotrophic
strains of S. Typhimurium like the SL7207 examined here
[27,33,34]. It has been reported for many species, including
strains of S. Typhimurium, that bacterial growth was confined to
necrotic regions of tumours, while in contrast, certain strains, such
as S. Typhimurium A1, have been shown to grow throughout the
tumour, including viable malignant tissue in a range of tumour
models [27,33,34,35,36,37]. In our previous studies, UCC2003
was detected solely in necrotic regions, as evidenced by PCR [19].
3D BLI combined with CT imaging provides in vivo evidence of
this here, with B. breve lux concentrated within the tumour. While
there was not enough resolution to detect capillaries and
microvasculature, larger vessels (near the tumour base) could be
readily resolved and segmented for visualization by mCT.
This study is not the first attempt to register 3D optical and
mCT images. Some studies have looked at specific integrated
instrumentation to combine fluorescence and mCT [38,39]. Other
studies have taken approaches similar to ours and transferred
animals between separate instruments and performed the
registration afterwards [40,41]. As with any unique imaging
approach there are limitations. The diffuse optical tomography
reconstruction algorithm used here assumes that tissue optical
properties are homogenous [21]. For the data presented here, GIT
imaging (Figure 3d) may also be biased by registration errors on
the order of 0.5 mm by going between two instruments [41].
When comparing optical reconstructions to the anatomical atlas,
visual interpretation at a gross scale provides reference of a
bioluminescent source reconstruction to the general anatomy. For
the subcutaneous 3D optical data (Figure 6), the spatial positioning
of the 3D optical signals has been shown to be accurate to the
order of 1–2 mm [24,42].
Though oxygen is involved in the lux enzymatic reaction, a
number of anaerobic bacteria have been successfully labelled with
lux, and shown to produce bioluminescence under the normal low
oxygen/anoxic growth condition of these bacteria [43]. Moreover,
bioluminescence from a number of pathogenic bacteria in the
supposed anaerobic environment of the GIT has been detected by
2D BLI [44,45,46]. In this study, we validate the functioning of lux
at low to negligible oxygen tensions. We imaged both commensal
strains in the mouse GIT in this study. 2D in vivo imaging of
another commensal E. coli strain, E. coli Nissle, has recently been
reported [47]. We report here, the novel ability to sub-localise
GIT regions of highest colonisation using 3D BLI.
Overall, we demonstrate the potential for non-pathogenic
bacteria as vectors for cancer therapy. Analysis of reporter gene
activity from these strains not only demonstrates their potential as
safe and non-invasive vectors, with the potential to deliver
therapeutic or diagnostic agents systemically but furthermore
underlines the significance of BLI and mCT co-registration as tools
to advance this concept.
Materials and Methods
Bacterial Strains
B. breve UCC2003 (UCC Culture Collection) was routinely
grown at 37uC in reinforced clostridial medium (RCM) (Oxoid,
Basingstoke, United Kingdom). For bioluminescence assays and
preparation of the bacteria for animal inoculations MRS medium
(Oxoid), supplemented with 0.05% (w/v) cysteine-HCl was used.
Anaerobic conditions were maintained using an anaerobic
chamber (Mac500, Don Whitley Scientific, West Yorkshire, UK
(atmosphere 10% H2, 10% CO2, 80% N2). B. breve UCC2003/
pLuxMC3 [25], expressing the plasmid based luxABCDE operon
from the Phelp promoter [30] was cultured in the presence of 4 mg/
ml chloramphenicol (Cm). To facilitate specific recovery of
bifidobacteria from tissue samples, 50 mg mupirocin (Oxoid)/litre
was included, as previously described [48].
An mCherry fluorescent B. breve UCC2003 was also generated.
700 base pair coding region encompassing the mCherry gene was
amplified by PCR from an mCherry plasmid obtained from Roger
Tsien [49], digested with KpnI and BamHI and ligated to a
similarly digested pSKEm [50], to generate pSKcherry. The
putative promoter region of repC from the B. catenulatum plasmid
pBC1 [51] was PCR amplified and digested with XhoI, and
ligated to pSKcherry digested with XhoI/EcoRV creating
pCheMC, before transformation of UCC2003 by electroporation.
E. coli K-12 MG1655 [52] containing the integrated luxABCDE
was grown aerobically at 37uC in LB medium (Sigma, Steinheim,
Germany) supplemented with 300 mg/ml erythromycin (Em). The
bioluminescent derivative of MG1655 was created using the
plasmid p16Slux which contains the constitutive PHELPluxABCDE
operon [30] on the backbone of pGh9::ISS1, a thermo-sensitive
shuttle vector which integrates randomly into the bacterial
chromosome as a consequence of the presence of ISS1 [53].
p16Slux was transformed into MG1655 by electroporation using
standard protocols essentially as described by Riedel et al. [54].
Integration of the plasmid was achieved by incubation of isolated
positive clones at temperature non-permissive to plasmid replica-
tion (42uC) under antibiotic selective pressure (erythromycin, Em).
EmR colonies were checked for light emission, and the integration
of p16Slux was confirmed by PCR using primers 16S_rev_XhoI
and 16S_fwd_int [54] yielding the expected 1,150-bp fragment.
The auxotrophic attenuated strain of Salmonella enterica serovar
Typhimurium designated SL7207 was received as a kind gift from
Dr. Bruce Stoker [55]. This strain was also transformed with
p16Slux by the same method, as previously described by our group
[56].
Tumour Cell lines and Culture
Murine Lewis Lung Carcinoma cells, B16-F10 cells and human
U87 glioblastoma cells (ATCC) were maintained in culture at
37uC in a humidified atmosphere of 5% CO2, in Dulbecco’s
Modified Essential Medium (GIBCO, Invitrogen Corp., Paisley,
Scotland) supplemented with 10% iron-supplemented donor calf
serum (Sigma Aldrich Ireland, Ireland), 300 mg/ml L-glutamine
and 100 U/ml penicillin and 100 mg/ml streptomycin.
FaDu hypopharyngeal carcinoma (ATCC) was maintained in
culture at 37uC in a humidified atmosphere of 5% CO2, in
Essential Medium Eagles Modification (Sigma) supplemented with
10% iron-supplemented donor calf serum (Sigma). The HCT116-
luc2 cell line (Caliper) was maintained in McCoy’s 5a Medium
Modified (ATCC) supplemented with 10% foetal calf serum (FCS),
100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine
and sodium pyruvate and grown at 37uC in a humidified
atmosphere of 5% CO2.
U87 cells stably expressing fLuc2 and GFP (U87-fLuc2/GFP)
were generated by overnight infection using an HIV-1-based
bicistronic lentiviral vector encoding both the firefly luciferase and
GFP genes under the control of the CMV promoter, with the GFP
gene translated from an internal ribosomal entry sequence (IRES).
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Greater than 90% transduction efficiency was confirmed by FACS
analysis for GFP expression.
Ethics Statement
All murine experiments were approved by the animal ethics
committee of University College Cork or Caliper IACUC animal
ethics committee. (AERR #2010/003 and ‘‘The use of bacteria as
gene vectors in anticancer therapy’’.)
Animals and Tumour Induction
Mice were kept at a constant room temperature (22uC) with a
natural day/night light cycle in a conventional animal colony.
Standard laboratory food and water were provided ad libitum. Before
experiments, the mice were afforded an adaptation period of at least
7 days. Female mice in good condition, without fungal or other
infections, weighing 16–22 g and of 6–8 weeks of age, were included
in experiments. For routine tumour induction, the minimum
tumourigenic dose of cells suspended in 200 ml of serum-free culture
mediumwas injected subcutaneously (s.c.) into the flank of 6–8 week
old female C57 or athymic MF1-nu/nu mice (Harlan, Oxfordshire,
UK) (16106 B16-F10 tumour cells, 56105 LLC) or athymic
Crl:NU(NCr)-Fox1nu mice (Charles River) (56105 U87, 7.56106
HCT116). The viability of cells used for inoculation was greater
than 95% as determined by visual count using a haemocytometer
and Trypan Blue Dye Exclusion (Gibco), or the Nucleocounter
system (ChemoMetec, Bioimages Ltd, Cavan, Ireland). Following
tumour establishment, tumours were allowed to grow and develop
and were monitored twice weekly. Tumour volume was calculated
according to the formula V= (ab2) P/6, where a is the longest
diameter of the tumour and b is the longest diameter perpendicular
to diameter a. When tumours reached approximately 100 mm3 in
volume, the mice were randomly divided into experimental groups.
Bacterial Administration
Inocula were prepared by growing B. breve UCC2003/
pLuxMC3 anaerobically overnight at 37uC in 100 ml of MRS
broth containing 4 mg/ml Cm and E. coli MG1655-luxABCDE and
SL7207 aerobically in 100 ml LB broth containing 300 mg/ml
Em. Cultures were harvested by centrifugation (6,0006g for
5 min), washed three times with PBS (PBS supplemented with
0.05% cysteine HCl (Sigma) for bifidobacteria), and resuspended
in a one-tenth volume of PBS. The viable count of each inoculum
was determined by retrospective plating on Reinforced Clostridial
Agar (RCA) containing 4 mg/ml Cm for B. breve or LB agar
containing 300 mg/ml Em for E. coli and SL7207.
For GIT colonisation studies, 109 bacterial cells were orally
administered in 100 ml per mouse by gavage, on three consecutive
days. In the case of E. coli studies, pre-existing commensal bacterial
levels were decreased prior to feeding by addition of 5 mg/ml
streptomycin in mouse drinking water for 7 days prior to
commencement of oral gavage.
For tumour-related studies, mice were randomly divided into
experimental groups when tumours reached approximately
100 mm3 in volume, and administered either B. breve, E. coli,
SL7207 or an equal volume of PBS as control. Each animal
received either 105 B. breve or 106 E. coli or 106 SL7207 in 100 ml
injected directly into the lateral tail vein.
Bacterial Recovery From Mice
At defined time points (Figure 1) following whole-body imaging,
a subset of animals from each group were euthanised by cervical
dislocation. Individual tumours as well as lungs, liver, spleen and
kidneys were aseptically removed. Each tissue was homogenized
by fine mincing by scalpel followed by pushing through a 20 mm
pore nylon filter (Falcon, Becton Dickinson (BD), Oxford,
England) in sterile PBS (supplemented with 0.05% cysteine-HCl
for bifidobacteria). Serial dilutions were plated in triplicate on
selective agar; B. breve on RCA agar containing 4 mg/ml Cm and
mupirocin and E. coli on LB agar containing 300 mg/ml Em.
Resulting colonies were used to calculate the number of bacterial
cells per tissue sample. To confirm that cfu recovered were either
B. breve containing pLuxMC3 or E. coli MG1655luxABCDE,
random isolates were spot inoculated onto the appropriate agar
either with or without the selective antibiotic.
Optical Image Acquisition And Image Formation
2D in vivo BLI imaging was performed using the IVIS100
(Caliper). At defined time points post bacterial administration,
animals were anesthetised by intraperitoneal administration of
200 mg xylazine and 2 mg ketamine, and whole-body image
analysis was performed in the IVIS 100 system for 2–5 minutes at
high sensitivity. Regions of interest were identified and quantified
using Living Image software (Caliper).
For 3D imaging, mice were anesthetized using Caliper’s XGI-8
Gas Anesthesia System with 3% Isofluorane and placed in a
mouse imaging shuttle inside of the optical imaging system for
dorsal imaging (IVIS Spectrum, Caliper). To acquire images of the
bacterial luciferase signal for 3D optical reconstruction, emission
filter wavelengths ranging from 500–580 nm were used with bin
16 acquisition times of 3–4 min per filter to maximize the signal to
noise ratio. To acquire images of the firefly luciferase emanating
from the tumour, luciferin was injected approximately 10 minutes
prior to imaging using a subcutaneous approach without moving
the animal. Emission filter wavelengths ranging from 580–620 nm
were then used with bin 8 acquisition times of 0.5–0.75 min per
filter. As part of this image acquisition sequence, a structured light
image was obtained to define a height map. This map was input
diffuse light imaging tomography (DLIT) reconstructions algo-
rithms that were used to form a 3D optical image using a non-
negative least squares optimization [21].
mCT Image Acquisition and Generation
While mice were still positioned in the shuttle, a preclinical
blood pooling contrast agent (exitron nano 12000, Miltenyi,
Auburn, CA, USA) was injected via the tail vein. The mouse was
then transferred to an in vivo mCT imaging system (Quantum FX,
Caliper) and the shuttle was positioned in a customized bed
containing a fiducial. One image of the entire mouse was acquired
and reconstructed into a 12 cm axial FOV image with an isotropic
voxel size of 295 um. To obtain a higher resolution image of the
tumour for vascular imaging, the mouse was then removed from
this shuttle and the magnification was increased to acquiring a
1 cm FOV image of the tumour that was reconstructed with a
20 mm isotropic voxel size. All images were reconstructed using
standard back-projection techniques.
Image Registration and Processing
To co-register the two DLIT 3D optical images with the whole
body mCT image, a customized registration routine was
implemented to detect the fiducial in the mCT holder for the
mouse imaging shuttle (Living Image, Caliper). This algorithm
detects the fiducial in the mCT image and then transforms this
image to match the identical orientation of the 3D optical image.
To overlay these 3D optical images with the high resolution mCT,
all images were then imported into a dedicated image processing
and visualization package (Avizo Fire, Visualization Sciences
Group). Using the whole mouse mCT as a reference frame, the
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bacterial DLIT, firefly DLIT signal and high-resolution mCT
images were separately registered using affine transformations
driven by optimization of a normalized mutual information
metric. To segment the vasculature in the high resolution mCT
image, an edge-preserving smoothing filter was applied prior to
use of a threshold limited semi-automatic region growing
approach to define the vasculature. A sequence of 3 dilations
and 3 erosions was then applied to remove any additional noise.
Finally, volume rendering was applied to show this vasculature
segmentation and the two DLIT signals overlaid with an isosurface
of the skin around the tumour.
Histological Analysis
For ex vivo histological analyses, s.c. U87/GFP tumours were
harvested 7, 11 and 14 days post administration with B. breve/
pCheMC. Resected tumours were fixed in 10% v/v buffered
formalin and embedded in paraffin. Serial 6 mm sections were cut at
tumour periphery and tumour centre and mounted on slides. To
detect mCherry labelled bacteria and GFP tumour cells on sections,
slides were deparaffinised and mounted with DAPI containing
media (Vector Lab, Burlingame, CA). GFP, mCherry and DAPI
signals were imaged with epifluorescence microscope (Nikon, E400)
equipped with a Nuance FX camera (Caliper). Nuance camera
contains liquid crystal tuneable filters that can enable spectral
unmixing for each fluorophore. Image analysis and spectral
unmixing was performed using InForm software (Caliper). Adjacent
sections were stained with H&E for morphological analysis.
Vasculature within tumours was examined by immunohisto-
chemistry (IHC) specific for murine CD31 (PCAM-1). Paraffin
embedding, sectioning and IHC were carried out by the
Translation Pathology Core at UCLA. Tissues were fixed in
10% formalin prior to paraffin embedding. Sections of 4 mm
thickness were subjected to immunohistochemical analysis. Briefly,
sections were deparaffinized using xylene and rehydrated by
passing through ethanol at concentrations ranging from 100% to
50%. Endogenous peroxidase activity was blocked in 3%
hydrogen peroxide in methanol for 10 min. Antigen retrieval
was achieved by incubation with citrate buffer at 95uC for 25 min.
The sections were incubated at RT for 2 hours with PCAM-1
(Santa Cruz Biotechnology, sc-1506) at the dilution of 1: 100. The
slides were rinsed with PBST (Phosphate Buffered Saline
containing 0.05% Tween-20), prior to 30 min incubation at RT
with a biotinylated polyclonal Rabbit anti-goat immunoglobulin
(Dako, E0466), at a dilution of 1:200. The sections were rinsed
with PBST, and were incubated with Dako EnVision+ System –
HRP Labelled Polymer Anti-Rabbit (Dako, K4003) for 30 min-
utes at RT. The sections were rinsed with PBST then incubated
with DAB (3,39-Diaminobenzidine) for visualisation. The sections
were washed in water, counterstained with Harris’ Hematoxylin,
dehydrated in ethanol, and mounted with media.
Statistical Analysis
Two-tailed Student’s t-tests were employed to investigate
statistical differences. Microsoft Excel 12 (Microsoft) was used to
manage and analyze data. Statistical significance was defined at
the standard 5% level.
Supporting Information
Movie S1 Bacterial Bioluminescence in the GIT. Movie
depicting rotational 3D optical tomography in combination with
mouse anatomical atlas displaying luminescence in GIT of mice 27
days post oral administration of lux-labelled E. coli MG1655.
(AVI)
Movie S2 3D Co-localisation of Tumour And Bacterial
Bioluminescence. Movie providing tomographic detail of
source signal distribution of B. breve lux (green) 10 days post IV
administration to mice bearing HCT116 FLuc (orange) expressing
tumours. B. breve lux is observed in multiple disparate ‘clusters’
within the tumour.
(MOV)
Movie S3 3D Intratumoural Optical and mCT Imaging.
Combined mCT and luminescence imaging of subcutaneous
HCT116-luc2 tumour colonised by B. breve. Viable tumour (FLuc
green/blue), vasculature (contrast agent – red) and bacterial
(orange/yellow) signals are visualised.
(MOV)
Figure S1 Tumour Vasculature Immunohistochemis-
try. Murine endothelial cells within U87 tumour were visualised
by IHC staining specific for CD31. Sections were incubated with
anti-PCAM-1 antibody, followed by secondary biotinylated
polyclonal Rabbit anti-goat immunoglobulin, and HRP-labelled
Polymer Anti-Rabbit and visualised with DAB counterstained with
Harris’ Hematoxylin. Endothelial cells stain brown.
(TIF)
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